Synta names new corporate development VP
This article was originally published in Scrip
Synta Pharmaceuticals, a biopharmaceutical company developing and commercializing small molecule drugs for conditions including cancer and chronic inflammatory diseases, has named Steven Bernitz senior vice-president of corporate development. Prior to joining the Lexington, Massachusetts-based firm, Mr Bernitz was a general partner and head of the BioPharm practice at Extera Partners, a business development advisory firm.
You may also be interested in...
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.